Drug-Drug Interaction Study Between Quinine Sulfate and Rosiglitazone

Phase 1 Completed 23 enrolled Mutual Pharmaceutical Company, Inc. Cetero Research, San Antonio · collab

Non-randomizedSingle-groupOpen-labelBasic science

Summary

Rosiglitazone is predominantly metabolized by cytochrome P450 (CYP) 2C8. Quinine sulfate is an inhibitor of CYP 2C8. This study will evaluate the effect of multiple doses of quinine sulfate at steady-state on the pharmacokinetics of single-dose rosiglitazone in healthy adult subjects.

Timeline

Start: 2008-09
Primary completion: 2008-10
Completion: 2008-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Quinine	Small molecule	648 mg	Oral
Subject	Rosiglitazone	Small molecule	4 mg	Oral

Indications

No indication recorded.